Lenvervimab Biosimilar - Research Grade

Human

HBV

>1mg/ml

IgG1 - kappa

CHO Cells

Exbivirumab Biosimilar - Research Grade (ICH5540), Libevitug Biosimilar - Research Grade (ICH5641), Libivirumab Biosimilar - Research Grade (ICH5642), Tobevibart Biosimilar - Research Grade (ICH5931), Tuvirumab Biosimilar - Research Grade (ICH5950)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of lenvervimab, supplied for research use only. Lenvervimab is a fully human recombinant anti-hepatitis B immunoglobulin (a recombinant HBIG) that binds the hepatitis B surface antigen (HBsAg), the envelope glycoprotein displayed on virions and subviral particles. Unlike plasma-derived HBIG, it is a defined, monoclonal-format recombinant protein with consistent affinity and avidity for HBsAg, making the research-grade analog a reproducible tool for studies of HBsAg engagement and virus neutralisation. As a human IgG1/kappa reagent it is useful as a positive binding control, a benchmarking antibody in HBsAg ELISA and surface-plasmon-resonance assays, a neutralisation reference in in-vitro infection models (e.g. HepG2-NTCP or primary hepatocyte systems), and a Fc-competent tool for ADCC/effector-function and antibody-engineering work. It is offered as an unconjugated preparation, low-endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg), available in bulk milligram-to-gram quantities. It is not the clinical drug and is not intended for human or veterinary use. ichorbio should review target assignment and copy before publishing. Hepatitis B virus (HBV) is a small enveloped DNA virus (family Hepadnaviridae) that causes acute and chronic liver infection. Its envelope carries the surface antigen (HBsAg), encoded by a single open reading frame that yields the large (L), middle (M) and small (S) surface proteins sharing the common S domain, with the L protein adding preS1/preS2 regions. HBsAg forms virions and vast excesses of non-infectious subviral spheres and filaments; the preS1 region mediates attachment to the hepatocyte receptor NTCP (SLC10A1). HBsAg is the principal neutralising target: antibodies to the conserved "a" determinant of the S domain block infection and drive viral clearance, and anti-HBs seroconversion is the serological hallmark of resolved infection and vaccine protection. Because HBV is a virus rather than a single human protein, no single human UniProt accession applies; the relevant antigen is the viral surface protein.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Lenvervimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Lenvervimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Lenvervimab biosimilar target?

A: It is a non-therapeutic biosimilar of Lenvervimab used as a binding and neutralization reagent against HBV; for research use only.